Dataset from A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009757
下载链接
链接失效反馈官方服务：
资源简介：
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study
of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus
with insufficient glycaemic control
创建时间：
2024-11-26
